We are live on ! Find out more
ABOS icon

Acumen Pharmaceuticals
ABOS

80 hedge funds and large institutions have $176M invested in Acumen Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 11

19% more funds holding

Funds holding: 67 → 80 (+13)

19% more capital invested

Capital invested by funds: $148M → $176M (+$27.9M)

5.76% more ownership

Funds ownership: 66.42% → 72.18% (+5.8%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

8% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 24

63% less call options, than puts

Call options by funds: $1.54M | Put options by funds: $4.13M

Holders
80
Holders Change
+13
Holders Change %
+19.4%
% of All Funds
1.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
24
Increased
22
Reduced
24
Closed
11
Calls
$1.54M
Puts
$4.13M
Net Calls
-$2.59M
Net Calls Change
+$1.17M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.87M
2
Millennium Management
Millennium Management
New York
+$4.28M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$4.14M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$778K
5
Goldman Sachs
Goldman Sachs
New York
+$766K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$882K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$658K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$530K
4
Citadel Advisors
Citadel Advisors
Florida
-$406K
5
SSA
Schonfeld Strategic Advisors
New York
-$388K
Name Holding Trade Value Shares
Change 		Change in
Stake
Qube Research & Technologies (QRT)
26
Qube Research & Technologies (QRT)
United Kingdom
$679K +$298K +78,962 +89%
TD Asset Management
27
TD Asset Management
Ontario, Canada
$603K +$561K +148,800 New
BCM
28
Bridgeway Capital Management
Texas
$601K +$559K +148,400 New
Citigroup
29
Citigroup
New York
$548K -$46.8K -12,417 -8%
Squarepoint
30
Squarepoint
New York
$459K +$228K +60,403 +114%
Wellington Management Group
31
Wellington Management Group
Massachusetts
$455K +$423K +112,258 New
HF
32
HRT Financial
New York
$425K +$396K +105,117 New
NYLIM
33
New York Life Investment Management
New York
$385K +$358K +95,089 New
Marshall Wace
34
Marshall Wace
United Kingdom
$363K +$338K +89,707 New
State Street
35
State Street
Massachusetts
$331K -$12.4K -3,300 -4%
Bank of America
36
Bank of America
North Carolina
$326K -$89.5K -23,753 -23%
CFP
37
Catalyst Financial Partners
Massachusetts
$311K – – –
JP Morgan Chase
38
JP Morgan Chase
New York
$291K +$143K +37,945 +112%
Balyasny Asset Management
39
Balyasny Asset Management
Illinois
$259K +$163K +43,371 +211%
SFI
40
Susquehanna Fundamental Investments
Pennsylvania
$253K +$236K +62,518 New
Dimensional Fund Advisors
41
Dimensional Fund Advisors
Texas
$250K +$22.4K +5,937 +11%
Manulife (Manufacturers Life Insurance)
42
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$243K +$226K +60,041 New
MTIM
43
Marathon Trading Investment Management
Pennsylvania
$243K +$226K +60,000 New
Northern Trust
44
Northern Trust
Illinois
$230K +$358 +95 +0.2%
BHCM
45
Brevan Howard Capital Management
Jersey
$228K +$212K +56,369 New
BFM
46
Boothbay Fund Management
New York
$209K -$115K -30,474 -37%
Morgan Stanley
47
Morgan Stanley
New York
$197K +$9.27K +2,460 +5%
Barclays
48
Barclays
United Kingdom
$192K -$139 -37 -0.1%
YIH
49
Y-Intercept (HK)
Hong Kong
$151K +$67.3K +17,843 +92%
PCM
50
Prelude Capital Management
New York
$150K +$29.8K +7,900 +27%
1
2
3 4

ABOS Hedge Fund Activity: Q1 2024 in Review

80 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q1 2024, worth a combined $176M — up 19% from $148M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ABOS positions and 11 closed out — a net gain of 13 holders — while 22 added to existing stakes and 24 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $7.87M. The largest seller was Susquehanna International Group, cutting an estimated $882K.

  • 80 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q1 2024, up from 67 in Q4 2023.
  • Funds reported $176M of Acumen Pharmaceuticals stock for Q1 2024, up 19% quarter-over-quarter.
  • 24 funds opened new Acumen Pharmaceuticals positions in Q1 2024 and 11 closed out, a net change of +13 holders.
  • The largest Acumen Pharmaceuticals buyer in Q1 2024 was Fidelity Investments, an estimated $7.87M added.
  • The largest Acumen Pharmaceuticals seller in Q1 2024 was Susquehanna International Group, an estimated $882K sold.

Based on aggregated 13F filings for Q1 2024.